688180 君实生物
已收盘 12-05 15:00:01
资讯
新帖
简况
君实生物(688180.SH):偌考奇拜单抗注射液新药上市申请获得受理
智通财经 · 17:27
君实生物(688180.SH):偌考奇拜单抗注射液新药上市申请获得受理
君实生物(688180)披露证券变动月报,12月4日股价上涨1.1%
证券之星 · 12-04 22:07
君实生物(688180)披露证券变动月报,12月4日股价上涨1.1%
君实生物:上海檀英减持1200万股完毕 占总股本的1.1688%
财中社 · 12-04 18:08
君实生物:上海檀英减持1200万股完毕 占总股本的1.1688%
君实生物:绿地金融投资控股集团有限公司及其一致行动人持股比例已降至4.71%
南方财经网 · 12-03 19:12
君实生物:绿地金融投资控股集团有限公司及其一致行动人持股比例已降至4.71%
港股生物医药板块持续走低,泰格医药、君实生物跌超3%
每日经济新闻 · 12-02
港股生物医药板块持续走低,泰格医药、君实生物跌超3%
君实生物(01877)拟使用暂时闲置募集资金进行现金管理
智通财经 · 11-27
君实生物(01877)拟使用暂时闲置募集资金进行现金管理
港股异动 | 君实生物(01877)再涨超5% 特瑞普利单抗皮下注射III期临床达主要终点 后续拟申报上市
智通财经 · 11-26
港股异动 | 君实生物(01877)再涨超5% 特瑞普利单抗皮下注射III期临床达主要终点 后续拟申报上市
港股异动 | 君实生物(01877)现涨近5% JS001sc肺癌III期临床达主要终点 公司近期将递交上市许可申请
智通财经 · 11-25
港股异动 | 君实生物(01877)现涨近5% JS001sc肺癌III期临床达主要终点 公司近期将递交上市许可申请
君实生物宣布JS001SC在非小细胞肺癌一线治疗的三期研究中满足主要终点
美股速递 · 11-25
君实生物宣布JS001SC在非小细胞肺癌一线治疗的三期研究中满足主要终点
君实生物 - JS001SC 一期临床研究达成非鳞状 NSCLC 一线治疗主要终点
美股速递 · 11-24
君实生物 - JS001SC 一期临床研究达成非鳞状 NSCLC 一线治疗主要终点
君实生物(688180.SH):JS001sc一线治疗非鳞状非小细胞肺癌的Ⅲ期临床研究达到主要研究终点
智通财经 · 11-24
君实生物(688180.SH):JS001sc一线治疗非鳞状非小细胞肺癌的Ⅲ期临床研究达到主要研究终点
港股异动 | 君实生物(01877)涨近3% 拓益用于一线治疗HER2表达尿路上皮癌新适应症获受理
智通财经 · 11-18
港股异动 | 君实生物(01877)涨近3% 拓益用于一线治疗HER2表达尿路上皮癌新适应症获受理
每周股票复盘:君实生物(688180)董事长增持10万股耗资383.84万元
证券之星 · 11-16
每周股票复盘:君实生物(688180)董事长增持10万股耗资383.84万元
君实生物(688180)披露2025年A股股票期权激励计划首次授予登记完成,11月14日股价下跌0.48%
证券之星 · 11-14
君实生物(688180)披露2025年A股股票期权激励计划首次授予登记完成,11月14日股价下跌0.48%
君实生物(688180)披露控股股东、实际控制人之一兼董事长增持股份进展公告,11月10日股价上涨1.59%
证券之星 · 11-10
君实生物(688180)披露控股股东、实际控制人之一兼董事长增持股份进展公告,11月10日股价上涨1.59%
君实生物 - 截至11月10日,董事长增持A股100,000股,交易总金额为380万元人民币
美股速递 · 11-10
君实生物 - 截至11月10日,董事长增持A股100,000股,交易总金额为380万元人民币
君实生物:11月10日高管熊俊增持股份合计10万股
证券之星 · 11-10
君实生物:11月10日高管熊俊增持股份合计10万股
每周股票复盘:君实生物(688180)H股及A股股本无变动
证券之星 · 11-09
每周股票复盘:君实生物(688180)H股及A股股本无变动
君实生物跌1.92% 连亏9年3季2020年上市2募资共86亿
中金财经 · 11-07
君实生物跌1.92% 连亏9年3季2020年上市2募资共86亿
君实生物(688180)披露证券变动月报表,11月3日股价下跌0.3%
证券之星 · 11-03
君实生物(688180)披露证券变动月报表,11月3日股价下跌0.3%
加载更多
公司概况
公司名称:
上海君实生物医药科技股份有限公司
所属行业:
医药制造业
上市日期:
2020-07-15
主营业务:
上海君实生物医药科技股份有限公司的主营业务是创新药物的发现和开发、在全球范围内的临床研究、大规模生产到商业化的全产业链。公司的主要产品是以源头创新、自主研发类生物制品为主,同时通过合作开发、设立合资企业以及许可(license-in)等形式引进与自有源创产品线有协同作用的药物或平台技术,进一步壮大产品管线。曾荣膺国家专利领域最高奖项“中国专利金奖”,并获得“十二五”、“十三五”两项“重大新药创制”国家重大科技专项支持。
发行价格:
55.50
{"stockData":{"symbol":"688180","market":"SH","secType":"STK","nameCN":"君实生物","latestPrice":36,"timestamp":1764918001000,"preClose":35.75,"halted":0,"volume":4356253,"delay":0,"changeRate":0.007,"floatShares":766000000,"shares":1027000000,"eps":-0.9252,"marketStatus":"已收盘","change":0.25,"latestTime":"12-05 15:00:01","open":35.75,"high":36.05,"low":35.19,"amount":155000000,"amplitude":0.0241,"askPrice":36.01,"askSize":11,"bidPrice":36,"bidSize":21,"shortable":0,"etf":0,"ttmEps":-0.9252,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1765157400000},"marketStatusCode":5,"adr":0,"adjPreClose":35.75,"symbolType":"stock_kcb","openAndCloseTimeList":[[1764898200000,1764905400000],[1764910800000,1764918000000]],"highLimit":39.33,"lowLimit":32.18,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":1026689871,"isCdr":false,"pbRate":5.95,"roa":"--","roe":"--","epsLYR":-1.3,"committee":-0.649891,"marketValue":36961000000,"turnoverRate":0.0057,"status":0,"afterMarket":{"amount":0,"volume":0,"close":36,"buyVolume":0,"sellVolume":0,"time":1764920037768,"indexStatus":"已收盘 12-05 15:30:00","preClose":35.75},"hkstockBrief":{"symbol":"01877","market":"HK","secType":"STK","nameCN":"君实生物","latestPrice":23.56,"timestamp":1764922148002,"preClose":23.96,"halted":0,"volume":2959200,"delay":0,"premium":"-40.59"},"floatMarketCap":27590000000},"requestUrl":"/m/hq/s/688180","defaultTab":"news","newsList":[{"id":"2589189805","title":"君实生物(688180.SH):偌考奇拜单抗注射液新药上市申请获得受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2589189805","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589189805?lang=zh_cn&edition=full","pubTime":"2025-12-05 17:27","pubTimestamp":1764926866,"startTime":"0","endTime":"0","summary":"智通财经APP讯,君实生物 发布公告,近日,公司收到国家药品监督管理局核准签发的《受理通知书》,公司产品偌考奇拜单抗注射液用于治疗适合系统治疗或光疗的中度至重度斑块状银屑病的成人患者的新药上市申请获得受理。截至公告披露日,除本次新药上市申请外,偌考奇拜单抗用于治疗活动性强直性脊柱炎的Ⅱ期临床研究的所有参与者已完成治疗,进入安全随访期。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1378190.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688180","01877","BK1583","BK1161","BK1515","BK0239"],"gpt_icon":0},{"id":"2588880821","title":"君实生物(688180)披露证券变动月报,12月4日股价上涨1.1%","url":"https://stock-news.laohu8.com/highlight/detail?id=2588880821","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588880821?lang=zh_cn&edition=full","pubTime":"2025-12-04 22:07","pubTimestamp":1764857238,"startTime":"0","endTime":"0","summary":"截至2025年12月4日收盘,君实生物报收于35.75元,较前一交易日上涨1.1%,最新总市值为367.04亿元。公司近日发布公告,披露截至2025年11月30日的证券变动月报。公告显示,君实生物H股和A股的法定/注册股本、已发行股份及库存股份数目均无变动。H股股票期权激励计划项下结存期权数目为13,210,000股,A股股票期权激励计划项下结存期权数目为24,700,000股,较上月减少450,000股,因部分期权注销所致。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120400039389.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688180","01877","BK1161","161027","BK1515","BK1583","BK0239"],"gpt_icon":0},{"id":"2588895883","title":"君实生物:上海檀英减持1200万股完毕 占总股本的1.1688%","url":"https://stock-news.laohu8.com/highlight/detail?id=2588895883","media":"财中社","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588895883?lang=zh_cn&edition=full","pubTime":"2025-12-04 18:08","pubTimestamp":1764842924,"startTime":"0","endTime":"0","summary":"12月4日,君实生物(688180/01877)发布公告,股东上海檀英通过大宗交易方式减持1200万股,占公司总股本的1.1688%。减持计划时间区间已届满。2025年前三季度,君实生物实现收入18.06亿元,归母净利润-5.96亿元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202512043582789075.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1161","BK0239","688180","BK1583","BK1515","01877"],"gpt_icon":0},{"id":"2588483710","title":"君实生物:绿地金融投资控股集团有限公司及其一致行动人持股比例已降至4.71%","url":"https://stock-news.laohu8.com/highlight/detail?id=2588483710","media":"南方财经网","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588483710?lang=zh_cn&edition=full","pubTime":"2025-12-03 19:12","pubTimestamp":1764760349,"startTime":"0","endTime":"0","summary":"南财智讯12月3日电,君实生物公告,因H股股份出借,绿地金融投资控股集团有限公司及其一致行动人上海加财投资管理有限公司、GreenlandFinancialOverseasInvestmentGroupCo.,Ltd的持股比例合计由5.0051%下降至4.7129%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202512033581707486.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1161","BK0239","01877","159940","BK1583","688180","BK1515"],"gpt_icon":0},{"id":"2588608692","title":"港股生物医药板块持续走低,泰格医药、君实生物跌超3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2588608692","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588608692?lang=zh_cn&edition=full","pubTime":"2025-12-02 11:49","pubTimestamp":1764647365,"startTime":"0","endTime":"0","summary":"港股生物医药板块持续走低,泰格医药、君实生物跌超3%","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202512023580206556.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202512023580206556.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1576","BK0077","161726","BK0028","LU1146622755.USD","399441","BK1515","LU1820825898.SGD","300347","BK0216","BK0239","BK1161","03347","BK1141","BK0174","BK1583","688180","01877"],"gpt_icon":0},{"id":"2586242593","title":"君实生物(01877)拟使用暂时闲置募集资金进行现金管理","url":"https://stock-news.laohu8.com/highlight/detail?id=2586242593","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586242593?lang=zh_cn&edition=full","pubTime":"2025-11-27 19:27","pubTimestamp":1764242829,"startTime":"0","endTime":"0","summary":"智通财经APP讯,君实生物(01877)发布公告,公司将按照相关规定严格控制风险,拟使用暂时闲置募集资金投资安全性高、流动性好的保本型投资产品(包括但不限于通知存款、定期存款、协定存款、组合存款、存单及结构性存款等),且该等产品不得用于质押,不用于以证券投资为目的的投资行为。公司计划使用最高不超过人民币24亿元(包含本数)的暂时闲置募集资金进行现金管理。根据募集资金使用情况以及公司经营情况,将暂时闲置募集资金分笔按不同期限投资上述产品,最长期限不超过12个月。在前述额度和期限内,资金可以循环滚动使用。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1374657.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","BK0239","BK1515","01877","688180","BK1583"],"gpt_icon":0},{"id":"2586284330","title":"港股异动 | 君实生物(01877)再涨超5% 特瑞普利单抗皮下注射III期临床达主要终点 后续拟申报上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2586284330","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586284330?lang=zh_cn&edition=full","pubTime":"2025-11-26 11:09","pubTimestamp":1764126584,"startTime":"0","endTime":"0","summary":"消息面上,君实生物宣布,由公司自主研发的特瑞普利单抗注射液对比特瑞普利单抗注射液联合化疗一线治疗复发或转移性非鳞状非小细胞肺癌的多中心、开放、随机对照Ⅲ期临床研究达到主要研究终点。君实生物计划将于近期向监管部门递交该产品的上市许可申请。公开资料显示,JS001sc是公司在已上市产品特瑞普利单抗注射液的基础上开发的皮下注射制剂,为首款进入III期临床研究阶段的国产抗 PD-1 单抗皮下制剂,有望给患者带来用药的便捷性。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1373733.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","III","BK0239","BK1583","01877","688180","BK1515","BK4134"],"gpt_icon":0},{"id":"2586540410","title":"港股异动 | 君实生物(01877)现涨近5% JS001sc肺癌III期临床达主要终点 公司近期将递交上市许可申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2586540410","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586540410?lang=zh_cn&edition=full","pubTime":"2025-11-25 10:21","pubTimestamp":1764037296,"startTime":"0","endTime":"0","summary":"消息面上,君实生物宣布,由公司自主研发的特瑞普利单抗注射液对比特瑞普利单抗注射液联合化疗一线治疗复发或转移性非鳞状非小细胞肺癌的多中心、开放、随机对照Ⅲ期临床研究达到主要研究终点。君实生物计划将于近期向监管部门递交该产品的上市许可申请。公告显示,JS001sc是公司在已上市产品特瑞普利单抗注射液的基础上开发的皮下注射制剂,为首款进入III期临床研究阶段的国产抗PD-1单抗皮下制剂,有望给患者带来用药的便捷性。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1373109.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1583","BK0239","688180","BK1515","III","BK4134","BK1161","01877"],"gpt_icon":0},{"id":"1168049853","title":"君实生物宣布JS001SC在非小细胞肺癌一线治疗的三期研究中满足主要终点","url":"https://stock-news.laohu8.com/highlight/detail?id=1168049853","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1168049853?lang=zh_cn&edition=full","pubTime":"2025-11-25 09:26","pubTimestamp":1764033982,"startTime":"0","endTime":"0","summary":"君实生物宣布JS001SC在非小细胞肺癌(NSQ-NSCLC)一线治疗的三期研究中已满足主要终点。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["688180","BK0239"],"gpt_icon":0},{"id":"1146313423","title":"君实生物 - JS001SC 一期临床研究达成非鳞状 NSCLC 一线治疗主要终点","url":"https://stock-news.laohu8.com/highlight/detail?id=1146313423","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1146313423?lang=zh_cn&edition=full","pubTime":"2025-11-24 21:01","pubTimestamp":1763989274,"startTime":"0","endTime":"0","summary":"君实生物 - JS001SC 一期临床研究达成非鳞状 NSCLC 一线治疗主要终点","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1515","688180","BK0239","BK1161","BK1583","01877"],"gpt_icon":0},{"id":"2585466361","title":"君实生物(688180.SH):JS001sc一线治疗非鳞状非小细胞肺癌的Ⅲ期临床研究达到主要研究终点","url":"https://stock-news.laohu8.com/highlight/detail?id=2585466361","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2585466361?lang=zh_cn&edition=full","pubTime":"2025-11-24 18:57","pubTimestamp":1763981876,"startTime":"0","endTime":"0","summary":"智通财经APP讯,君实生物 发布公告,近日,公司产品特瑞普利单抗注射液对比特瑞普利单抗注射液联合化疗一线治疗复发或转移性非鳞状非小细胞肺癌的多中心、开放、随机对照III期临床研究达到主要研究终点。截至公告披露日,一项对比JS001sc和特瑞普利单抗注射液联合化疗一线治疗复发或转移性非鳞状非小细胞肺癌的多中心、开放、随机对照III期临床研究已达到主要研究终点。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1372868.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1583","BK1161","BK0239","01877","BK1515","688180"],"gpt_icon":0},{"id":"2584609037","title":"港股异动 | 君实生物(01877)涨近3% 拓益用于一线治疗HER2表达尿路上皮癌新适应症获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2584609037","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2584609037?lang=zh_cn&edition=full","pubTime":"2025-11-18 09:43","pubTimestamp":1763430217,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,君实生物涨近3%,截至发稿,涨1.62%,报25.14港元,成交额542.37万港元。消息面上,长江证券指出,君实生物的营收增长以特瑞普利单抗(拓益)为核心,2025年前三季度在国内实现销售收入约14.95亿元,同比增长约40%。2025年第三季度,拓益用于一线治疗HER2表达尿路上皮癌的新适应症获得国家药品监督管理局受理。截至2025年第三季度,国内已获批12项适应症,其中10项适应症已纳入国家医保目录。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1370335.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1515","BK1583","688180","BK1161","BK0239","01877"],"gpt_icon":0},{"id":"2583651839","title":"每周股票复盘:君实生物(688180)董事长增持10万股耗资383.84万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2583651839","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583651839?lang=zh_cn&edition=full","pubTime":"2025-11-16 03:04","pubTimestamp":1763233456,"startTime":"0","endTime":"0","summary":"股本股东变化高管增减持2025年11月10日,君实生物董事长熊俊增持公司股份10.0万股,占总股本0.0097%。公司公告汇总君实生物关于控股股东、实际控制人之一兼董事长增持股份进展公告董事长熊俊自2025年4月12日起12个月内拟增持公司股份,合计不少于1亿元,其中A股不低于5000万元。截至2025年11月11日,已通过集中竞价累计增持A股100,000股,约占总股本0.01%,累计成交金额383.84万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111600000696.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1161","BK0239","688180","BK1583","BK1515","01877"],"gpt_icon":0},{"id":"2583502392","title":"君实生物(688180)披露2025年A股股票期权激励计划首次授予登记完成,11月14日股价下跌0.48%","url":"https://stock-news.laohu8.com/highlight/detail?id=2583502392","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583502392?lang=zh_cn&edition=full","pubTime":"2025-11-14 22:30","pubTimestamp":1763130648,"startTime":"0","endTime":"0","summary":"截至2025年11月14日收盘,君实生物报收于39.01元,较前一交易日下跌0.48%,最新总市值为400.51亿元。公告显示,公司已完成2025年A股股票期权激励计划首次授予登记工作。首次授予登记日为2025年11月14日,授予股票期权数量为2,470.00万份,激励对象共计226人,授予价格为46.67元/股,股票来源为公司向激励对象定向发行A股普通股。等待期分别为12个月和24个月,分两个行权期各行权50%。因9名激励对象放弃期权,原计划调整后完成登记。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111400041847.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688180","159982","399300","BK1161","01877","BK0239","BK1583","BK1515"],"gpt_icon":0},{"id":"2582877131","title":"君实生物(688180)披露控股股东、实际控制人之一兼董事长增持股份进展公告,11月10日股价上涨1.59%","url":"https://stock-news.laohu8.com/highlight/detail?id=2582877131","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2582877131?lang=zh_cn&edition=full","pubTime":"2025-11-10 22:30","pubTimestamp":1762785045,"startTime":"0","endTime":"0","summary":"截至2025年11月10日收盘,君实生物报收于38.39元,较前一交易日上涨1.59%,最新总市值为394.15亿元。公司近日发布公告称,控股股东、实际控制人之一兼董事长熊俊先生自2025年4月12日起12个月内拟增持公司股份,合计增持金额不低于人民币1亿元,其中A股不低于5000万元。截至公告披露日,熊俊已通过集中竞价方式累计增持A股100,000股,约占公司总股本的0.01%,累计成交金额383.84万元。本次增持计划尚未实施完毕,熊俊将继续择机增持。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111000034821.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["01877","BK1161","BK0239","BK1515","BK1583","688180"],"gpt_icon":0},{"id":"1116298315","title":"君实生物 - 截至11月10日,董事长增持A股100,000股,交易总金额为380万元人民币","url":"https://stock-news.laohu8.com/highlight/detail?id=1116298315","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1116298315?lang=zh_cn&edition=full","pubTime":"2025-11-10 20:00","pubTimestamp":1762776059,"startTime":"0","endTime":"0","summary":"君实生物 - 截至11月10日,董事长增持A股100,000股,交易总金额为380万元人民币","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1583","01877","688180","BK1161","BK0239","BK1515"],"gpt_icon":0},{"id":"2582827064","title":"君实生物:11月10日高管熊俊增持股份合计10万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2582827064","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2582827064?lang=zh_cn&edition=full","pubTime":"2025-11-10 19:01","pubTimestamp":1762772503,"startTime":"0","endTime":"0","summary":"证券之星消息,根据11月10日市场公开信息、上市公司公告及交易所披露数据整理,君实生物最新董监高及相关人员股份变动情况:2025年11月10日公司董事长熊俊共增持公司股份10.0万股,占公司总股本为0.0097%。变动期间公司股价上涨1.59%,11月10日当日收盘报38.39元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111000027342.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1161","BK0239","688180","BK1583","BK1515","01877"],"gpt_icon":0},{"id":"2582669518","title":"每周股票复盘:君实生物(688180)H股及A股股本无变动","url":"https://stock-news.laohu8.com/highlight/detail?id=2582669518","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2582669518?lang=zh_cn&edition=full","pubTime":"2025-11-09 01:43","pubTimestamp":1762623789,"startTime":"0","endTime":"0","summary":"截至2025年11月7日收盘,君实生物报收于37.79元,较上周的40.37元下跌6.39%。本周关注点公司公告汇总:君实生物H股及A股股本截至2025年10月31日无变动。已发行股份总数无变化,H股为260,295,700股,A股为766,394,171股,其中A股库存股为815,871股。股份期权计划方面,H股及A股股票期权激励计划于2025年9月29日获批准采纳,本月无新增股份或库存股转让。本月底法定/注册股本总额为人民币1,026,689,871元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110900000250.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688180","BK1161","BK1515","159982","BK1583","01877","399300","BK0239"],"gpt_icon":0},{"id":"2581006562","title":"君实生物跌1.92% 连亏9年3季2020年上市2募资共86亿","url":"https://stock-news.laohu8.com/highlight/detail?id=2581006562","media":"中金财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2581006562?lang=zh_cn&edition=full","pubTime":"2025-11-07 18:21","pubTimestamp":1762510893,"startTime":"0","endTime":"0","summary":"中国经济网北京11月7日讯 君实生物 今日收报37.79元,跌幅1.92%。该股目前处于破发状态。 上市首日,君实生物股价最高报220.40元,为上市以来股价最高点。 君实生物首次公开发行股票募集资金总额为48.36亿元,扣除发行费用后,募集资金净额为44.97亿元,较原计划多17.97亿元。 君实生物首次公开发行股票募的发行费用为3.39亿元,其中,保荐及承销费用3.20亿元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushijujiao/20251107/31777126.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["688180","BK1515","01877","BK1161","BK1583","BK0239"],"gpt_icon":0},{"id":"2580211626","title":"君实生物(688180)披露证券变动月报表,11月3日股价下跌0.3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2580211626","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2580211626?lang=zh_cn&edition=full","pubTime":"2025-11-03 22:22","pubTimestamp":1762179777,"startTime":"0","endTime":"0","summary":"截至2025年11月3日收盘,君实生物报收于40.25元,较前一交易日下跌0.3%,最新总市值为413.24亿元。公司近日发布公告,披露截至2025年10月31日的证券变动月报表。公告显示,君实生物普通股H股和A股的法定/注册股本无变动。A股于上海证券交易所科创板上市,证券代码688180,上月底结存及本月底结存均为766,394,171股,其中A股库存股为815,871股。已发行股份总数中,H股为260,295,700股,A股为766,394,171股。本月底法定/注册股本总额为人民币1,026,689,871元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110300035918.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["161027","BK1515","BK1583","688180","01877","BK0239","BK1161"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1764948753301,"stockEarnings":[{"period":"1week","weight":-0.0353},{"period":"1month","weight":-0.0847},{"period":"3month","weight":-0.2552},{"period":"6month","weight":0.0804},{"period":"1year","weight":0.1615},{"period":"ytd","weight":0.3081}],"compareEarnings":[{"period":"1week","weight":0.0001},{"period":"1month","weight":-0.0213},{"period":"3month","weight":0.0166},{"period":"6month","weight":0.1449},{"period":"1year","weight":0.1519},{"period":"ytd","weight":0.1563}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"上海君实生物医药科技股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"35877人(较上一季度增加15.17%)","perCapita":"21361股","listingDate":"2020-07-15","address":"上海市浦东新区中国(上海)自由贸易试验区蔡伦路987号4层","registeredCapital":"102668万元","survey":" 上海君实生物医药科技股份有限公司的主营业务是创新药物的发现和开发、在全球范围内的临床研究、大规模生产到商业化的全产业链。公司的主要产品是以源头创新、自主研发类生物制品为主,同时通过合作开发、设立合资企业以及许可(license-in)等形式引进与自有源创产品线有协同作用的药物或平台技术,进一步壮大产品管线。曾荣膺国家专利领域最高奖项“中国专利金奖”,并获得“十二五”、“十三五”两项“重大新药创制”国家重大科技专项支持。","listedPrice":55.5},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.9","shortVersion":"4.35.9","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"君实生物(688180)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供君实生物(688180)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"君实生物,688180,君实生物股票,君实生物股票老虎,君实生物股票老虎国际,君实生物行情,君实生物股票行情,君实生物股价,君实生物股市,君实生物股票价格,君实生物股票交易,君实生物股票购买,君实生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"君实生物(688180)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供君实生物(688180)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}